|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030
Joseph Mantil, M.D., Ph.D., Kettering Medical Center
Dr. Mantil has been Director of the Kettering Medical Center Department of Nuclear Medicine and
PET since 1986, and is Clinical Professor of Medicine and Chief of the Division of Nuclear Medicine
at Wright State University School of Medicine. He has served as the Principal investigator for
numerous PET imaging research studies focused on the central nervous system, oncology, and
cardiology. These studies have involved a spectrum of radiotracers incorporating radioisotopes of
carbon, fluorine, oxygen, nitrogen, and other chemistries. Dr. Mantil is board certified in internal
medicine and nuclear medicine.
Wallace Mendelson, M.D., University of Chicago (ret.)
Dr. Mendelson is an expert in the development and marketing of therapeutics for sleep disorders,
including sleep aids and antidepressants. He is Professor of Psychiatry and Clinical Pharmacology
(ret.) at the University of Chicago, a consultant to pharmaceutical companies, and a member of the
editorial board of the Internal Journal of Sleep and Wakefulness. He was previously Director of the
Sleep Research Laboratory at the University of Chicago, Chief of the Section on Sleep Studies at the
National Institute of Mental Health, Director of the Sleep Laboratory at the Cleveland Clinic, and
former President of the Sleep Research Society.
Dr. Mosconi is Assistant Professor in the Department of Psychiatry at New York University. Her
research interests include PET and MRI imaging in the early diagnosis of Alzheimer’s Disease. She
has developed novel approaches to automatically and reliably sample brain regions of interest on
PET scans in patients with highly varying degrees of atrophy. She has also demonstrated the very
early prediction of dementia and the accurate classification of dementia types using PET imaging.
Her work includes the diagnostic application of MRI and CSF markers, and translation of image
sampling and analysis methods to preclinical (animal) models of Alzheimer’s Disease. Dr.
Mosconi holds a Ph.D. degree in Neuroscience and Nuclear Medicine from the University of
Florence, Italy, in association with New York University School of Medicine.
Lisa Mosconi, Ph.D., New York University Center for Brain Health
Masanori Ichise, M.D., Ph.D., FRCPC, Columbia University
Dr. Ichise is Medical Director of the Morton A. Kreitchman PET Center, Professor of Clinical Radiology
at Columbia University College of Physicians and Surgeons, and Co-director of the Division of
Nuclear Medicine. An internationally recognized researcher in PET and SPECT imaging of patients
with neuropsychiatric disorders such as Alzheimer’s and Parkinson’s diseases, he is well known for
his expertise in the quantification of imaging results. He has authored numerous articles and
pioneered multiple techniques for PET/SPECT analysis of brain chemistry. Before coming to
Columbia, he was Director of the Brain Molecular Imaging Program at Brigham and Women’s
Hospital in Boston and conducted research at Harvard Medical School. Previously, he was a
molecular imaging principal investigator at the NIH.
Howard Fillit, MD, a geriatrician and neuroscientist, is the founding Executive Director of the Institute
for the Study of Aging (ISOA), an Estée Lauder family foundation founded in 1998, and the Alzheimer’s
Drug Discovery Foundation (ADDF), an affiliated public charity founded in 2004. ISOA and ADDF share
a common mission of accelerating drug discovery for Alzheimer’s disease through venture
philanthropy. Dr. Fillit was previously the Corporate Medical Director for Medicare at NYLCare Health
Plans (acquired by Aetna, Inc. in 1998), responsible for over 125,000 Medicare members in several
regional markets. He has had a distinguished academic medicine career, previously at The
Rockefeller University, and currently at The Mount Sinai School of Medicine where he is a clinical
professor of geriatrics and medicine and professor of neurobiology. He is the author or co-author of
more than 250 scientific and clinical publications, and has received several awards and honors
including the Rita Hayworth Award for Lifetime Achievement from the Alzheimer’s Association. He also
serves as a consultant to pharmaceutical and biotechnology companies, health care organizations
Howard Fillit, MD, Alzheimer's Drug Discovery Foundation
Mony deLeon, PhD, New York University Center for Brain Health
Dr. Mony de Leon is Professor of Psychiatry at the New York University (NYU) School of Medicine and
Scientist at the New York State, Nathan Kline Institute. He received his Gerontology doctorate from
Columbia University in 1980. His published doctoral dissertation described, for the first time, the
cortical atrophy of Alzheimer’s disease in living patients. For over 25 years he has continued to
develop imaging and biomarker approaches for the early diagnosis of Alzheimer’s disease (AD).
Among his qualifications, he has published over 200 papers in AD research and founded both the
NYU Neuroimaging laboratory and the NYU School of Medicine, Center for Brain Health (CBH). The
CBH is an interdisciplinary clinical research center, funded by the NIH. Dr. de Leon is a reviewer
and/or editorial board member for 22 journals and has served on both national and international NIH
advisory panels in the area of the early diagnosis of AD. In 2006, he was voted “Worlds pioneer in the
brain imaging of Alzheimer’s disease” at the Alzheimer centennial in Tubingen, Germany.